
An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.
“What really needs to be done to show that this works is to look prospectively,” says Amar U. Kishan, MD.
In this video, Amar U. Kishan, MD, discusses the takeaways of the study, “Germline variants disrupting microRNAs predict long-term genitourinary toxicity after prostate cancer radiation.” Kishan is an associate professor in the department of radiation oncology, chief of genitourinary oncology service, and vice chair of clinical and translational research at the University of California, Los Angeles.






